| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1012305707 |
| P356 | DOI | 10.2165/11599100-000000000-00000 |
| P698 | PubMed publication ID | 22480319 |
| P5875 | ResearchGate publication ID | 223961889 |
| P50 | author | Peter Mol | Q56998618 |
| P2093 | author name string | Pieter A de Graeff | |
| Menno E van der Elst | |||
| Flora M Haaijer-Ruskamp | |||
| Jonie T N de Vries | |||
| Sabine M J M Straus | |||
| Sigrid Piening | |||
| P2860 | cites work | Timing of new black box warnings and withdrawals for prescription medications | Q28216033 |
| Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States | Q31107935 | ||
| Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007 | Q33327179 | ||
| Thrombotic thrombocytopenic purpura induced by ticlopidine: the power of "dear health professional" letters | Q33333329 | ||
| Effect of the British warning on contraceptive use in the General Medical Service in Ireland | Q33539396 | ||
| The immediate effects of the pill safety scare on usage of combined oral contraceptives in north east England | Q33704391 | ||
| Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone | Q34123137 | ||
| A study of compliance with FDA recommendations for pemoline (Cylert). | Q34137803 | ||
| Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters | Q34334572 | ||
| Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents | Q34582162 | ||
| Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors | Q35083808 | ||
| Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing | Q35561863 | ||
| Detection, verification, and quantification of adverse drug reactions | Q35615527 | ||
| Interrupted time series designs in health technology assessment: lessons from two systematic reviews of behavior change strategies | Q35750543 | ||
| Communication of medical product risk: how effective is effective enough? | Q35778956 | ||
| Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants | Q35896311 | ||
| Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid program | Q35951667 | ||
| Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions | Q36065199 | ||
| Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics | Q36408688 | ||
| Oral contraceptive use before and after the latest pill scare in The Netherlands. Changes in oral contraceptive use and how users change | Q74741092 | ||
| Official warnings on thromboembolism risk with oral contraceptives fail to inform users adequately | Q78550812 | ||
| Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs | Q80412509 | ||
| Effect of regulatory warnings on antidepressant prescribing for children and adolescents | Q80558017 | ||
| The population impact on incidence of suicide and non-fatal self harm of regulatory action against the use of selective serotonin reuptake inhibitors in under 18s in the United Kingdom: ecological study | Q36491695 | ||
| Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults | Q36512651 | ||
| Antidepressants in children and adolescents--changes in utilisation after safety warnings | Q36792735 | ||
| Telithromycin: the perils of hasty adoption and persistence of off-label prescribing | Q36867249 | ||
| Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | Q37240896 | ||
| Selective serotonin re-uptake inhibitor warnings and trends in exposures reported to poison control centres in Texas | Q37244899 | ||
| Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database | Q37351686 | ||
| Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds | Q37427952 | ||
| Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study | Q37471109 | ||
| Persisting decline in depression treatment after FDA warnings | Q37504480 | ||
| Decreased Use of Antidepressants in Youth After US Food and Drug Administration Black Box Warning. | Q37654990 | ||
| Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives | Q38559589 | ||
| Patterns and utilization of isotretinoin for acne from 1984 to 2003: is there need for concern? | Q39759816 | ||
| A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009. | Q39871580 | ||
| The impact of the October 1995 'pill scare' on oral contraceptive use in the United Kingdom: analysis of a general practice automated database | Q40885371 | ||
| Use of terfenadine and contraindicated drugs | Q40977668 | ||
| Coprescription of terfenadine and erythromycin or ketaconazole: an assessment of potential harm | Q41213768 | ||
| Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. | Q41854298 | ||
| Effect of CSM's warning about safety of third generation oral contraceptive. General practitioners in England prescribed second generation pills instead | Q43189172 | ||
| Terminations of pregnancy, not unplanned deliveries, increased as result of pill scare | Q43190044 | ||
| Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy | Q43579312 | ||
| Liver enzyme monitoring in patients treated with troglitazone | Q43702652 | ||
| Coprescribing and codispensing of cisapride and contraindicated drugs | Q43755682 | ||
| Use of cisapride with contraindicated drugs in The Netherlands | Q43888420 | ||
| Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy | Q43961933 | ||
| Impact of safety alerts upon prescribing of cisapride to children in New Zealand. | Q44166721 | ||
| Impact of cisapride label changes on codispensing of contraindicated medications. | Q44481515 | ||
| Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone | Q45037773 | ||
| Effects of Food and Drug Administration warnings on antidepressant use in a national sample | Q46818954 | ||
| Effects of the Committee on Safety of Medicines advice on antidepressant prescribing to children and adolescents in the UK. | Q46836809 | ||
| Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs | Q46911904 | ||
| Spillover effects on treatment of adult depression in primary care after FDA advisory on risk of pediatric suicidality with SSRIs | Q50147822 | ||
| Trends in conceptions before and after the 1995 pill scare. | Q51100493 | ||
| Co-dispensing of contraindicated medications in patients using cisapride in Italy. | Q51805289 | ||
| The effect of antidepressant warnings on prescribing trends in Ontario, Canada. | Q51906428 | ||
| Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions | Q58974605 | ||
| Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union | Q63865834 | ||
| Safety-related regulatory actions for orphan drugs in the US and EU: a cohort study | Q64043095 | ||
| Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin | Q73047678 | ||
| Contraindicated use of cisapride: impact of food and drug administration regulatory action | Q73310907 | ||
| Drug labeling revisions-guaranteed to fail? | Q73310923 | ||
| Segmented regression analysis of interrupted time series studies in medication use research | Q74601008 | ||
| P433 | issue | 5 | |
| P921 | main subject | systematic review | Q1504425 |
| P304 | page(s) | 373-385 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Impact of safety-related regulatory action on clinical practice: a systematic review | |
| P478 | volume | 35 |
| Q40924344 | Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions |
| Q30660881 | Automatic detection of adverse events to predict drug label changes using text and data mining techniques |
| Q38816487 | Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications |
| Q57293615 | Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK |
| Q92297426 | Cyclo-oxygenase selectivity and chemical groups of nonsteroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase |
| Q38762034 | Decrease in Switches to 'Unsafe' Proton Pump Inhibitors After Communications About Interactions with Clopidogrel |
| Q90648158 | Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands |
| Q40649706 | Effects of safety warnings and risk management plan for Thiazolidinediones in Taiwan. |
| Q38691137 | Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome |
| Q36342841 | Evaluating the effectiveness of risk minimisation measures: the application of a conceptual framework to Danish real-world dabigatran data |
| Q43828480 | Evaluation of two Japanese regulatory actions using medical information databases: a 'Dear Doctor' letter to restrict oseltamivir use in teenagers, and label change caution against co-administration of omeprazole with clopidogrel |
| Q43237199 | Focusing on risk communication about medicines: why now? |
| Q44014115 | Have antiepileptic drug prescription claims changed following the FDA suicidality warning? An evaluation in a state Medicaid program |
| Q48861311 | Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment |
| Q38737370 | Impact of Safety-Related Regulations on Codeine Use in Children: A Quasi-Experimental Study Using Taiwan's National Health Insurance Research Database |
| Q51061508 | Impact of an intervention on the prescription of aliskiren after new evidence on safety reported. |
| Q39711572 | Impact of rosiglitazone safety alerts on oral antidiabetic sales trends: a countrywide study in Portugal. |
| Q30810766 | Implementation of warnings from Dear Doctor Letters (Rote-Hand-Briefe): an analysis of medication data from a large cohort of elderly patients |
| Q52638852 | Listen to the public and fulfil their information interests - Translating vaccine communication research findings into guidance for regulators. |
| Q47309145 | Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning |
| Q47653552 | Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations |
| Q53403274 | Media Coverage of FDA Drug Safety Communications about Zolpidem: A Quantitative and Qualitative Analysis. |
| Q39014657 | Non-steroidal anti-inflammatory drug administration after coronary artery bypass surgery: utilization persists despite the boxed warning. |
| Q38752166 | Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study |
| Q38981425 | Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature. |
| Q57037781 | Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron |
| Q35595713 | Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial |
| Q37591802 | Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel - proton pump inhibitor interaction. |
| Q91835209 | Prevalence of, and factors associated with health supplement use in Dubai, United Arab Emirates: a population-based cross-sectional study |
| Q53122388 | Risk Communication and the Pharmaceutical Industry: what is the reality? |
| Q52676212 | Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study. |
| Q34389980 | Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS) |
| Q47619604 | Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs |
| Q92282804 | Systems Pharmacogenomic Landscape of Drug Similarities from LINCS data: Drug Association Networks |
| Q39397168 | The Additional Value of an E-Mail to Inform Healthcare Professionals of a Drug Safety Issue: A Randomized Controlled Trial in the Netherlands |
| Q47110995 | The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin |
| Q37683523 | The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. |
| Q86524099 | The cost-effectiveness of periodic safety update reports for biologicals in Europe |
| Q40597331 | The effectiveness and limitations of regulatory warnings for the safe prescribing of citalopram. |
| Q30907640 | The effectiveness of risk communication regarding drug safety information: a nationwide survey by the Japanese public health insurance claims data |
| Q34503444 | The increase in prescriptions of bisphosphonates and the incidence proportion of osteonecrosis of the jaw after risk communication activities in Japan: a hospital-based cohort study |
| Q39422837 | The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist |
| Q86207642 | When direct health-care professional communications have an impact on inappropriate and unsafe use of medicines |
Search more.